Hjem › Crohns sykdom › Indiana
Kliniske studier for Crohns sykdom i Indiana
13 studier for Crohns sykdom søker deltakere på steder i Indiana.
Byer i Indiana
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07697456Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
RekruttererFase 3
Alder 3 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06663332Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 24. jun. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Riley Hospital for Children at Indiana University Health, Indianapolis
RekruttererFase 4
Alder 6 til 17 · Alle kjønn · Oppdatert 27. mai 2026 · NCT05781152Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
RekruttererFase 2/3
Alder 6 til 22 · Alle kjønn · Oppdatert 5. mai 2026 · NCT05660746Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.